-
Loading metrics
Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself
- Cian M. McCrudden,
- Martin G. O’Rourke,
- Kim E. Cherry,
- Hiu-Fung Yuen,
- Declan O’Rourke,
- Muhammad Babur,
- Brian A. Telfer,
- Huw D. Thomas,
- Patrick Keane,
- Thiagarajan Nambirajan
x
- Published: February 17, 2015
- https://doi.org/10.1371/journal.pone.0118187